The Craneware Group’s Clinical Solutions Team is excited to share new research exploring the use of midodrine in adult patients with septic shock on vasopressor therapy.
Research presented at ASHP Midyear 2022 looks at the use of sodium-glucose cotransporter-2 inhibitors in acute heart failure in the largest real-world data study population.
Signed on Aug. 17, 2022, the Inflation Reduction Act (IRA) is a pivotal piece of legislation. Despite being principally intended to combat inflation, it focuses on taxes, climate change, and healthcare in its 755 pages.
The Craneware Group’s Oncology Principal, Bonnie Labdi, PharmD, BCOP, recently served as a panelist on a Pharmacy Times Continuing Education presentation.
Join us for our webinar on Wednesday, Sept. 7 at 11:00 AM EST, Optimizing Biosimilar Use – Transforming Data and Insight into Action, to learn how your organization can evaluate and optimize biosimilar therapies saving up to 30% in cost.
The Craneware Group and Long Island University (LIU) Pharmacy Fellowship in Health Analytics and Artificial Intelligence (AI) are thrilled to share findings from the team’s third research project, presented at the 2022 American Association of Colleges of Pharmacy’s Pharmacy Education Conference.
The ASHP Foundation 2022 Pharmacy Forecast devotes considerable space to the issue of resilience, no surprise considering the last two years.
The ASHP Foundation recently released its annual Pharmacy Forecast for 2022, and this year’s report brought a heavy focus on social determinants of health.
In just over one month, our research team developed and executed a project to assess the real-world uptake of rituximab versus biosimilar products for oncology vs. non-oncology indications.
As part of our commitment to continuous improvement, we’re excited to announce a new enhancement to CRCA P&T, our comprehensive, real-world pharmacy analytics platform.